VIVUS, Inc. (VVUS): This Obesity Bet Just Became More Attractive

The importance of an FDA drug approval cannot be denied, but it is also a fact that the event can have different effects on the stock price. The ideology of buying on the rumor and selling on the news is a major factor when it comes to stock slides after drug approvals. This is because Investors sometimes prefer taking profits after approvals and sell the stock on the approval news. This is of course only applicable to small-cap biopharmaceutical companies, where valuations are entirely dependent on a single drug approval.

VIVUS, Inc. (NASDAQ:VVUS)Despite approval, there is still no guarantee that a specific drug will finally live up to expectations, no matter how much analysts think it will earn. Recent examples of this phenomenon are the below par sales of VIVUS, Inc. (NASDAQ:VVUS)’s Qsymia and the failure of Pfizer’s Inc. (NYSE:PFE) Exubera. These drugs were being hailed as billion dollar star products that demanded sky high valuations of their respective stocks. The reality however was different; Exubera was canceled after extremely poor sales figures, especially when analysts had predicted stellar sales of above $2 billion. However, being one of the largest biopharmaceutical companies in the world has its advantages. The loss of a multi-billion drug could have annihilated any other developer but Pfizer has not even been fazed by this loss. The company is still one of the best biopharmaceutical bets on the block and is a strong buy. Pfizer doesn’t only have a very strong pipeline and chances for capital appreciation, but also an attractive dividend yield of 3.6%.

These examples demonstrate effectively the unpredictability of actual commercial success of a drug. The most important factor at the end of the day is the willingness of insurers to provide coverage and doctors to prescribe the drug. Qsymia was being valued pretty high by analysts but the stock has depreciated significantly since FDA approval. As I mentioned above, the two primary constraints to Vivus appreciation are the insurance coverage and the willingness of doctors to prescribe the drug.

Vivus

Qsymia is still fighting to penetrate the obesity market, and despite mediocre sales, it’s still too soon to write it off completely. The company is facing tough competition from its archrival and competitor Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Belviq is a safer product as compared to Qsymia but is also less effective. Arena stock has been suspended between $8 and $12 despite stellar analyst ratings. This is because compared to Qsymia, Belviq is safer but also less effective.

As opposed to Arena, Vivus has taken a beating after poor sales results of Qsymia. However, a recent filling shows that sales are finally picking up. According to data released by the company, shipments for the period ending 12/21/12 were 12,978 as compared to 7,749 in the previous period, an increase of approx. 68%.

The company has also released data for its study on the effect of Qsymia on weight loss. According to company disclosures, the study shows that treatment with Qsymia led to significant improvements in blood pressure, triglycerides and cholesterol in obese patients suffering from one or more of these ailments. Moreover, the positive effects were even more exaggerated in patients who lost 10% or greater weight during the treatment.

According to an investigator in the study, Suzanne Oparil, M.D. (Director of the Vascular Biology and Hypertension Program, University of Alabama at Birmingham):

“This provides clear evidence that patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors.”

This should be exciting news for Vivus investors because it gives doctors more reason to recommend weight loss drugs to their obese patients. I reiterate my buy rating on Vivus due to my belief that Vivus has a greater ability to reduce weight as compared to alternatives, and new studies should reduce doctor reluctance in prescribing the drug.

The article This Obesity Bet Just Became More Attractive originally appeared on Fool.com and is written by Mohsin Saeed.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!